

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.11.27.~2023.12.03.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06153095	A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)	Biological: IMPT-514	ImmPACT Bio	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06153095
NCT06150183	Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors	Biological: BNT314 Biological: Pembrolizumab	BioNTech SE Genmab	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06150183
NCT06096038	Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC	Drug: Cyclophosphamide Drug: Fludarabine Biological: Cell Therapy	UNC Lineberger Comprehensive Cancer Center Bellicum Pharmaceuticals University Cancer Research Fund at Lineberger Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06096038
NCT06066359	Phase I/II Randomized Trial of Cord Blood-derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma	Drug: Fludarabine phosphate Drug: Cyclophosphamide Drug: NY-ESO-1 TCR/IL-15 NK	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06066359
NCT06027879	Anti-viral T-cell Therapy by Gamma Capture	Biological: Specific T- Lymphocytes	Paul Szabolcs University of Pittsburgh	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06027879
NCT05936229	Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	Biological: Interferon Beta-1A Procedure: X-Ray Imaging Procedure: Echocardiography Procedure: Multigated Acquisition Scan Procedure: Computed Tomography Procedure: Positron Emission Tomography Procedure: Lumbar Puncture Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Biospecimen Collection Procedure: Biopsy	Fred Hutchinson Cancer Center Faron Pharmaceuticals Ltd	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05936229
NCT05153304	Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers	Biological: personalized vaccine Drug: Nivolumab	Ezra Cohen University of California, San Diego	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05153304
NCT05110742	Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignancies	Drug: Fludarabine Phosphate Drug: Cyclophosphamide Drug: CAR.5/IL15-transduced CB-NK cells	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05110742
NCT05107934	Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis	Biological: RPH-104 Drug: Placebo	R-Pharm Overseas, Inc. Data Management 365 Keystat, LLC R-Pharm	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05107934
NCT03733067	Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency	Drug: abatacept Other: Placebo	National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT03733067

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05625633	Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts	Biological: Human Papillomavirus 9-valent Vaccine, Recombinant Other: Normal Saline	Western Institute for Veterans Research University of Utah Merck Sharp & Dohme LLC	Phase 2 Phase 3	
NCT06151847	Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	Procedure: Biospecimen Collection Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Biological: Interleukin-2 Biological: Lifileucel Procedure: Magnetic Resonance Imaging Procedure: Multigated Acquisition Scan Procedure: Tumor Resection	University of Kansas Medical Center National Cancer Institute (NCI) Iovance Biotherapeutics, Inc.	Phase 2	
NCT06138132	A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis	Biological: KYV-101 anti-CD19 CAR-T cell therapy Drug: Standard lymphodepletion regimen	Stanford University Kyverna Therapeutics	Phase 1	
NCT06126354	Dexamethasone/Pancreatic Clamp P&F	Drug: Insulin human Drug: Octreotide Acetate Drug: Glucagon Drug: Human Growth Hormone Drug: Dexamethasone Oral Other: [6,6-2H2] D-glucose Drug: 20% D-glucose (aq) Dietary Supplement: BOOST Plus Device: Harvard Apparatus PHD ULTRA CP syringe pump Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer Other: Normal saline Other: Human albumin	Columbia University Albert Einstein College of Medicine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	
NCT06076837	The Seven Trial: Exploiting the Unfolded Protein Response	Drug: Botenslimab Drug: Balstilimab Drug: Chloroquine Phosphate Drug: Celecoxib	HonorHealth Research Institute Translational Genomics Research Institute University of Arizona Agenus Inc.	Phase 1	
NCT06058663	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma	Procedure: Angiography Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Durvalumab Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Tremelimumab Procedure: Yttrium-90 Microsphere Radioembolization	Mayo Clinic	Phase 1	
NCT06046482	Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma	Drug: Pembrolizumab Drug: Magrolimab Drug: cetuximab Drug: Docetaxel	M.D. Anderson Cancer Center Gilead Sciences	Phase 2	
NCT06046287	Daratumumab for Polyneuropathy Associated With MGUS	Drug: Daratumumab and hyaluronidase-fihj	Georgetown University Janssen, LP	Phase 2	
NCT06027268	Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer	Drug: Trilaciclib Drug: Pembrolizumab Drug: Gemcitabine Drug: Carboplatin	Wake Forest University Health Sciences Merck Sharp & Dohme LLC G1 Therapeutics, Inc.	Phase 2	
NCT06015893	Semaglutide Therapy for Alcohol Reduction (STAR)	Behavioral: Take Control Drug: Semaglutide	National Institute on Drug Abuse (NIDA) National Institutes of Health Clinical Center (CC)	Phase 2	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06042725	Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Chest Radiography Procedure: Computed Tomography Biological: Daratumumab Drug: Dexamethasone Drug: Lenalidomide Procedure: Low Dose Computed Tomography of the Whole Body Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Drug: Venetoclax Procedure: X-Ray Imaging	Mayo Clinic	Phase 1	
NCT06015724	Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer	Drug: Daratumumab Biological: KRAS vaccine Drug: Nivolumab	Georgetown University Bristol-Myers Squibb Janssen, LP Targovax ASA	Phase 2	
NCT06007417	A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency	Drug: GenSci004 Drug: Genotropin	Changchun GeneScience Pharmaceutical Co., Ltd.	Phase 3	
NCT06005818	Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)	Drug: Pembrolizumab injection	University of Alabama at Birmingham	Phase 2	
NCT06005324	Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer	Drug: Paclitaxel Drug: Carboplatin Drug: Cetuximab Radiation: Standard Dose Radiation Radiation: Low Dose Radiation Drug: Cisplatin Drug: TFHX Regimen	University of Chicago	Phase 1	
NCT06001658	Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers	Drug: Gemcitabine Drug: Cisplatin Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme LLC	Phase 2	
NCT05989828	A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer	Biological: Aldesleukin Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Magnetic Resonance Imaging Procedure: Mammogram Procedure: Multigated Acquisition Scan Procedure: Ultrasound Imaging	University of Southern California National Cancer Institute (NCI)	Phase 1	
NCT05967299	Study of Intravenous ZMA001 in Healthy Subjects	Drug: ZMA001 (BC-NKA-20008) Other: Placebo	National Heart, Lung, and Blood Institute (NHLBI) Zymedi, Co., Ltd. National Institutes of Health Clinical Center (CC)	Phase 1	
NCT05945875	Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer	Drug: Panitumumab-IRDye800 Other: Indium In 111 Panitumumab Procedure: Single Photon Emission Computed Tomography Procedure: Computed Tomography Procedure: Resection Procedure: Fluorescence Imaging	Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)	Phase 1	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05935774	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Biological: Atezolizumab Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Other: Electronic Health Record Review Procedure: Magnetic Resonance Imaging Drug: Trabedersen (OT-101)	University of Washington Genentech, Inc. Oncotelic Therapeutics, Inc.	Phase 2	
NCT05931393	Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)	Drug: Cabozantinib 80 MG Drug: Cabozantinib 40Mg Tab Drug: Nivolumab	University of Texas Southwestern Medical Center Exelixis	Phase 2	
NCT05913388	GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma	Drug: GB1211 Drug: Pembrolizumab Drug: Placebo	Providence Health & Services Providence Cancer Center Providence Cancer Center, Earle A. Chiles Research Institute Galecto Biotech AB	Phase 2	
NCT05907746	Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency	other: Exercise Session Drug: Ibuprofen 800 mg Other: Rest Drug: Placebo	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	
NCT05900648	Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)	Drug: Regorafenib Drug: XmAb20717	M.D. Anderson Cancer Center Xencor, Inc. Bayer	Phase 2	
NCT05892432	Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)	Drug: Semaglutide 3 MG [Rybelsus] Drug: Semaglutide 7 MG [Rybelsus] Drug: Placebo	University of Colorado, Denver National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	
NCT05887609	An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib	Drug: Mirvetuximab Soravtansine Drug: Olaparib	University of Colorado, Denver ImmunoGen, Inc.	Phase 2	
NCT05887167	Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies	Biological: autologous hematopoietic stem cells added to planned CAR T	Joshua Sasine, MD, PhD Cedars-Sinai Medical Center	Phase 1	
NCT05847569	Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma	Biological: Belantamab Mafodotin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	Mayo Clinic	Phase 2	
NCT05802056	Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis	Biological: Aldesleukin Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Diagnostic Laparoscopy Drug: Fluorouracil Drug: Leucovorin Calcium Procedure: Magnetic Resonance Imaging Biological: Nivolumab Drug: Oxaliplatin Procedure: Positron Emission Tomography	Mayo Clinic	Phase 1	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05776277	Iltamioceol Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury	Biological: Iltamioceol Other: Placebo	Cook MyoSite	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05776277
NCT05775718	Shingrix In Recipients of Allogeneic Transplants	Drug: Zoster Vaccine Recombinant	University of Colorado, Denver GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05775718
NCT05766371	Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer	Drug: Pembrolizumab Drug: 177Lu-PSMA-617	University of California, San Francisco Merck Sharp & Dohme LLC Prostate Cancer Foundation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05766371
NCT05733689	Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	Device: ctDNA Blood Test Combination Product: FLOT Combination Product: FOLFIRI Combination Product: FOLFIRINOX Combination Product: PACLITAXEL with or without CARBOPLATIN Combination Product: DOCETAXEL and IRINOTECAN (alone or combined) Drug: NIVOLUMAB (alone or when added to a regimen above) Drug: PEMBROLIZUMAB (alone or when added to a regimen above)	University of California, Irvine Natera, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05733689
NCT05717140	Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	Biological: Aerosol Sargramostim Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Other: Medical Device Usage and Evaluation Biological: Nivolumab	Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05717140
NCT05676749	C-TIL051 in Non-Small Cell Lung Cancer	Biological: C-TIL051	Cellular Biomedicine Group, Inc. Nektar Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05676749
NCT05655949	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio	Drug: Gemcitabine Drug: Cisplatin Drug: Durvalumab Radiation: Yttrium-90	Beth Israel Deaconess Medical Center AstraZeneca Sirtex Medical Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05655949
NCT05632315	PMT for MDRO Decolonization	Drug: PMT	University of Pennsylvania	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05632315
NCT05535855	UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1	Drug: CD19 Directed CAR T Cell	University of Colorado, Denver	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05535855
NCT05491226	Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation	Drug: Pembrolizumab Radiation: Radiation Therapy Drug: Axatilimab	Stephen Shiao Merck Sharp & Dohme LLC Incyte Corporation Cedars-Sinai Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05491226
NCT04903795	Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma	Drug: hEGFRVIII-CD3 (BRiTE)	Duke University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04903795

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04881240	Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia	Biological: CD19-CAR(Mem) T-cells Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Device: CliniMACS Procedure: Leukapheresis	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04881240
NCT04645602	Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement	Drug: Lenvatinib Drug: Pembrolizumab	Massachusetts General Hospital Eisai Inc. Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04645602
NCT04254419	Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas	Biological: NK cells	Nationwide Children's Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04254419
NCT04044534	Intranasal Insulin for Posttraumatic Stress Disorder	Drug: Intranasal insulin Drug: Placebo	VA Connecticut Healthcare System	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04044534
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Biological: Cellular therapy product	Leland Metheny Case Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03939585
NCT06047977	Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors	Biological: Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2	Johns Hopkins All Children's Hospital Swim Across America Foundation Benjamin Gilkey Fund Cannonball Kids' Cancer Foundation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06047977
NCT06006013	Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer	Biological: Atezolizumab Procedure: Biospecimen Collection Drug: Cabozantinib S-malate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging	Emory University National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06006013
NCT05951777	Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury	Biological: Autologous HB-adMSCs Drug: Normal Saline	Hope Biosciences The University of Texas Health Science Center, Houston	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05951777
NCT05922501	Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma	Drug: Isatuximab Drug: Belantamab mafodotin Drug: Pomalidomide Drug: Dexamethasone	Massachusetts General Hospital Sanofi GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05922501
NCT05911308	Pilot Study of ABequolixron (RGX-104) and Durvalumab in Lung Cancer	Drug: Durvalumab Drug: Carboplatin Drug: ABequolixron Drug: Abraxane Drug: Pemetrexed	UNC Lineberger Comprehensive Cancer Center AstraZeneca Rgenix, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05911308
NCT05656235	Renal Retention in High Grade Upper Tract Urothelial Cancer	Drug: Enfortumab vedotin Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Astellas Pharma Inc Seagen Inc. Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05656235
NCT05355272	Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)	Drug: Recombinant human growth hormone Drug: Placebo	Baylor College of Medicine United States Department of Defense	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05355272

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05354544	Evaluating Autologous Stromal Vascular Fraction in Subjects With Vocal Fold Scar	Biological: Autologous adipose derived SVF	Shane A. Shapiro Mayo Clinic	Phase 1	
NCT04563520	SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis	Drug: aPCC-emicizumab Drug: FEIBA Drug: rFVIIa	Emory University Takeda Pharmaceuticals North America, Inc.	Phase 3	
NCT06104618	Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis	Drug: Enfortumab Vedotin	Mayo Clinic	Phase 2	
NCT05983133	A Study of SGN-EGFRd2 in Advanced Solid Tumors	Drug: SGN-EGFRd2	Seagen Inc.	Phase 1	
NCT05967416	Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma	Biological: SIRPant-M Radiation: External-beam radiotherapy (XRT)	SIRPant Immunotherapeutics, Inc.	Phase 1	
NCT05730712	Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPER Study	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Echocardiography Drug: Enzalutamide Drug: Hyaluronidase-zzxf Pertuzumab Trastuzumab Procedure: Magnetic Resonance Imaging Other: Questionnaire Administration	Mayo Clinic	Phase 2	
NCT05356897	Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	Biological: Trastuzumab Drug: Trifluridine and Tipiracil Hydrochloride Drug: Tucatinib	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	
NCT05145816	Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis	Drug: Belantamab mafodotin 2.5 mg/kg (6 weeks) Drug: Belantamab mafodotin 2.5 mg/kg (4 weeks) Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks) Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks) Drug: Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages	University of Texas Southwestern Medical Center GlaxoSmithKline	Phase 1 Phase 2	
NCT06088979	A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease	Drug: TOUR006 - 20 MG Other: Placebo Drug: TOUR006 - 50 MG	Tourmaline Bio, Inc.	Phase 2	
NCT05859217	A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)	Drug: Cabozantinib Drug: Atezolizumab	Jun Zhang, MD, PhD Exelixis Genentech, Inc. University of Kansas Medical Center	Phase 2	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 91건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05567835	A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer	Drug: Fluorouracil Drug: Leucovorin Drug: Oxaliplatin Drug: Docetaxel Biological: GSCF	Baylor College of Medicine	Phase 2	
NCT06127043	A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)	Drug: Rosnilimab Drug: Placebo	AnaptysBio, Inc.	Phase 2	
NCT05977907	Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).	Drug: Pembrolizumab Drug: IO102-103	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins IO Biotech Merck Sharp & Dohme LLC	Phase 2	
NCT05973487	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Biological: TSC-204-A0201 Biological: TSC-204-C0702 Biological: TSC-200-A0201 Biological: TSC-204-A0201 + TSC-204-C0702 Biological: TSC-204-A0201 + TSC-200-A0201 Biological: TSC-204-A0201 + TSC-203-A0201 Biological: TSC-204-C0702 + TSC-203-A0201 Biological: TSC-200-A0201 + TSC-203-A0201	TScan Therapeutics, Inc.	Phase 1	
NCT05952804	IVIg for Infection Prevention After CAR-T-Cell Therapy	Biological: Immune Globulin Infusion (Human), 10% Solution Biological: Anti-CD19-targeting CAR-T Cells Other: Saline Procedure: Biospecimen Collection Other: Survey Administration Other: Electronic Health Record Review	Fred Hutchinson Cancer Center Takeda National Cancer Institute (NCI)	Phase 2	
NCT05896670	Safety and Efficacy of Licamnimab Ophthalmic Suspension for the Treatment of Dry Eye Disease	Drug: licamnimab Other: vehicle of OCS-02	Oculis ORA, Inc.	Phase 2	
NCT05682443	ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC	Drug: ONC-392 Drug: lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.	OncoC4, Inc. Prostate Cancer Clinical Trials Consortium	Phase 1 Phase 2	
NCT06046274	GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Biological: Pembrolizumab Biological: Acasunlimab	Genmab BioNTech SE	Phase 2	
NCT06112314	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)	Biological: IMC-F106C Biological: Nivolumab Biological: Nivolumab + Relatlimab	Immunocore Ltd	Phase 3	
NCT06075745	Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates	Drug: CMV-MVA Triplex Drug: Placebo for CMV-MVA Triplex	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	
NCT06123338	A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer	Drug: Pembrolizumab Drug: Trastuzumab	Memorial Sloan Kettering Cancer Center Genentech, Inc. Merck Sharp & Dohme LLC	Phase 2	
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Procedure: Biospecimen Collection Drug: Cyclophosphamide Drug: Doxorubicin Biological: Durvalumab Other: Genetic Testing Procedure: Mammography Drug: Paclitaxel Other: Quality-of-Life Assessment	National Cancer Institute (NCI)	Phase 3	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 미국 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06008093	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients	Drug: Durvalumab Drug: Tremelimumab Drug: Pemetrexed Drug: Pembrolizumab Drug: Carboplatin Drug: Cisplatin	AstraZeneca	Phase 3	
NCT06003231	A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2	Drug: disitamab vedotin	Seagen Inc.	Phase 2	
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Drug: Volrustomig Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Nivolumab Drug: Ipilimumab	AstraZeneca	Phase 3	
NCT06014762	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	Biological: P-CD19CD20-ALLO1 Drug: Rimiducid	Poseida Therapeutics, Inc. Roche-Genentech	Phase 1	
NCT05748197	A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia	Biological: ADCLEC.syn1 CAR T cells Drug: Conditioning chemotherapy	Memorial Sloan Kettering Cancer Center Takeda	Phase 1	
NCT02546102	Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma	Biological: ICT-107 Biological: Placebo	Precision Life Sciences Group Medelis Inc.	Phase 3	
NCT06149403	A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT	Genetic: Experimental: OTL-203 Genetic: Active Comparator: Allo-HSCT	Orchard Therapeutics	Phase 3	

○ 영국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Drug: Volrustomig Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Nivolumab Drug: Ipilimumab	AstraZeneca	Phase 3	
NCT06112314	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)	Biological: IMC-F106C Biological: Nivolumab Biological: Nivolumab + Relatlimab	Immunocore Ltd	Phase 3	
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	
NCT06149403	A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT	Genetic: Experimental: OTL-203 Genetic: Active Comparator: Allo-HSCT	Orchard Therapeutics	Phase 3	
NCT06154837	A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease	Drug: GSK3862995B Drug: Placebo	GlaxoSmithKline	Phase 1	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 프랑스 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06152523	Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer	Drug: Monalizumab/MEDI5257	Assistance Publique - Hôpitaux de Paris	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06152523
NCT05998187	Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections	Drug: intra-rectal botulinum toxin injections	University Hospital, Rouen	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05998187
NCT06152731	HRD Tests for Ovarian cancer	Genetic: tests to determine HRD status	Centre Francois Baclesse	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06152731
NCT05821231	Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma	Combination Product: SBRT + MEDI5752	Institut Claudius Regaud National Cancer Institute, France AstraZeneca	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05821231
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Drug: Volrustomig Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Nivolumab Drug: Ipilimumab	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06097728
NCT06112314	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)	Biological: IMC-F106C Biological: Nivolumab Biological: Nivolumab + Relatlimab	Immunocore Ltd	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06112314
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05718297

○ 독일 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05843877	Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periapillary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula	Biological: Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy Procedure: Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)	Technische Universität Dresden KKS Dresden German Cancer Research Center	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05843877
NCT05836896	A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies	Genetic: MDC-CAR-BCMA001 (BCMA directed CAR T-cells)	Technische Universität Dresden German Cancer Research Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05836896
NCT04837859	Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma	Drug: Tislelizumab	University of Cologne	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04837859
NCT05662904	Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML	Biological: Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion Drug: Gemtuzumab Ozogamicin	German Cancer Research Center University Hospital Heidelberg University Hospital Dresden	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05662904
NCT05704829	NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer	Drug: Trastuzumab deruxtecan Drug: Standard-of-Care	West German Study Group AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05704829

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 독일 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06112314	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)	Biological: IMC-F106C Biological: Nivolumab Biological: Nivolumab + Relatlimab	Immunocore Ltd	Phase 3	
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Drug: Volrustomig Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Nivolumab Drug: Ipilimumab	AstraZeneca	Phase 3	

○ 중국 35건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06140576	The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.	Drug: Sindilimab Drug: Nab-paclitaxel Drug: Lenvatinib	Zhejiang Cancer Hospital	Phase 1 Phase 2	
NCT06139211	A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors	Biological: JS015 Biological: Toripalimab Biological: Paclitaxel Drug: Irinotecan Drug: Capecitabine Drug: Oxaliplatin Biological: Bevacizumab Drug: Fluorouracil Drug: Leucovorin Drug: Gemcitabine Drug: Albumin-Bound Paclitaxel	Shanghai Junshi Bioscience Co., Ltd. Sponsor GmbH	Phase 1 Phase 2	
NCT06131450	A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies	Drug: BL-M07D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	
NCT06114511	A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer	Drug: BL-M07D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	
NCT03184935	Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)	Biological: Allogeneic umbilical cord mesenchymal stem cells Drug: Decitabine	Sclnow Biotechnology Co., Ltd.	Phase 1 Phase 2	
NCT03180463	The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)	Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Procedure: core decompression	Sclnow Biotechnology Co., Ltd.	Phase 1 Phase 2	
NCT03180450	The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)	Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Drug: conventional treatment	Sclnow Biotechnology Co., Ltd.	Phase 1 Phase 2	
NCT03176498	Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.	Biological: Allogeneic umbilical cord mesenchymal stem cell Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium	Sclnow Biotechnology Co., Ltd.	Phase 1 Phase 2	
NCT06154707	Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes	Drug: Denosumab Injection Other: Normal saline injection (1.0ml/ branch)	Wuhan Union Hospital, China	Phase 3	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 중국 35건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06152822	Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases	Drug: pyrotinib+capecitabine+bevacizumab	Tongji Hospital	Phase 2	
NCT06151743	Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma	Drug: three cycles (toripalimab + cetuximab + platinum) Procedure: Radical surgery Radiation: Radiotherapy or chemoradiotherapy	Eye & ENT Hospital of Fudan University	Phase 2	
NCT06149130	Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer	Drug: Adebrelimab Drug: dalpiciclib	Tongji Hospital	Phase 2	
NCT06142617	A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.	Drug: Pembrolizumab, pemetrexed, platinum Drug: Osimertinib	Peking Union Medical College Hospital	Phase 2	
NCT06134765	Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer	Drug: Bemalenograstim alfa	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2	
NCT06123663	A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over	Biological: TTVA Biological: TT	CanSino Biologics Inc.	Phase 1	
NCT06120751	A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over	Biological: TTVA Biological: TT	CanSino Biologics Inc.	Phase 3	
NCT06107114	Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma	Drug: Cetuximab Drug: Zimberelimab Drug: Docetaxel Drug: Cisplatin	Xuekui Liu Sun Yat-sen University	Phase 2	
NCT06083870	An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC	Drug: Oba01	Lu Shun Shanghai Chest Hospital	Phase 1	
NCT06051760	NV-001 in the Treatment of Advanced Solid Tumors	Biological: NV-001	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 1	
NCT06042894	A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT06014775	Anti-CD38 Antibody Treating Evans Syndrome	Drug: Anti-CD38 antibody Injection	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	
NCT06010875	A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors	Biological: CD70 CAR-T cells	Chongqing Precision Biotech Co., Ltd The First Affiliated Hospital of Nanchang University	Phase 1	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 중국 35건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06008054	A Study of SI-B003 and BL-B01D1+SI-B003 in the Treatment of Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors	Drug: SI-B003 Drug: BL-B01D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT05965856	A Study of SI-B003 and BL-B01D1+SI-B003 in the Treatment of Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	
NCT05860569	Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis	Genetic: GC304	GeneCradle Inc	Phase 1	
NCT05477927	Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases	Biological: Dual-targeting VEGFR1 and PD-L1 CAR-T cells	Sichuan University	Phase 1	
NCT06136988	A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.	Drug: Docetaxel for Injection (Albumin-bound) Drug: SG001 Drug: Cisplatin for injection Drug: Paclitaxel Radiation: Simultaneous Radiotherapy	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1 Phase 2	
NCT03902067	UC-MSC Transplantation for Left Ventricular Dysfunction After AMI	Biological: UC-MSC Biological: Control Group	Shanghai Life Science & Technology Shanghai Jiao Tong University Affiliated Sixth People's Hospital	Phase 1	
NCT03186456	The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife@-ACI) in the Treatment of Acute Cerebral Infarction	Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) Drug: Aspirin Tablet	Sclnow Biotechnology Co., Ltd.	Phase 1	
NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular-based Stagingcarcinoma	Drug: Vedolizumab Drug: larotininib or entraitinib Drug: antiandrogen drug treatment Drug: SHR-A1921 Drug: small molecule multi-target tyrosine kinase inhibitors Drug: albumin paclitaxel with platinum	Peking Union Medical College Peking University Hospital of Stomatology	Phase 2	
NCT06056804	Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer	Drug: capecitabine Drug: tislelizumab Drug: thymalfasin Radiation: long-term radiotherapy	Beijing Friendship Hospital Peking Union Medical College Hospital	Phase 2	
NCT06139536	Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients	Drug: BAT4706 Injection Drug: BAT1308 Injection	Bio-Thera Solutions	Phase 1	
NCT06107686	A Study of YL202 in Selected Patients With Advanced Solid Tumors	Drug: YL202 should be intravenously infused	MediLink Therapeutics (Suzhou) Co., Ltd.	Phase 2	

해외 바이오의약품 임상 현황 ('23년 11월 5주)

한국바이오의약품협회, 2023.12.05.

○ 중국 35건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06079983	JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects	Drug: JSKN003 Drug: Capecitabine tablets Drug: Gemcitabine hydrochloride for injection Drug: Vinorelbine tartrate injection Drug: Paclitaxel for injection (albumin-bound type) Drug: Docetaxel injection Drug: Eribulin mesylate injection	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Phase 3	
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Drug: Volrustomig Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Nivolumab Drug: Ipilimumab	AstraZeneca	Phase 3	

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Drug: Volrustomig Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Nivolumab Drug: Ipilimumab	AstraZeneca	Phase 3	